Bortezomib is a proteasome inhibitor used in the treatment of multiple myeloma and mantle cell lymphoma. It works by blocking the proteasome, a complex that degrades proteins in cells, which leads to the accumulation of damaged proteins and ultimately cell death. It is used as part of combination therapies in cancer treatment.
Cleanchem is a trusted provider of premium pharmaceutical reference materials, specializing in Bortezomib and its associated compounds. Our catalog includes pharmacopeial and non-pharmacopeial Bortezomib impurities, metabolites, nitrosamine derivatives (N-NO compounds), and stable isotope-labeled products. These reference standards play a critical role in pharmaceutical R&D, supporting activities such as product formulation, ANDA and DMF submissions, quality assurance, analytical method development, and stability assessments.
All Bortezomib-related substances undergo comprehensive characterization and are delivered with complete Certificates of Analysis and supporting analytical documentation to ensure regulatory adherence. Upon request, we can offer EP/USP traceable standards. Our products are routinely re-evaluated to maintain consistent quality and performance.
English
Arabic
Chinese (Simplified)
French
Japanese
Portuguese
Russian
Spanish
